Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PROTEAse Inhibitor (DRV/Rtv) in Mono- or Triple Therapy in Suppressed HIV-1 Infected Subjects

Next Previous
X
Search
Trial Profile

PROTEAse Inhibitor (DRV/Rtv) in Mono- or Triple Therapy in Suppressed HIV-1 Infected Subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darunavir (Primary) ; Ritonavir (Primary) ; Abacavir; Emtricitabine; Lamivudine; Tenofovir disoproxil fumarate; Zidovudine
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms PROTEA
  • Sponsors Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 17 Jul 2019 Results of a retrospective nested study assessing HIV-1 reservoir levels as possible markers for virological failure during boosted darunavir monotherapy, published in the Journal of Antimicrobial Chemotherapy
    • 16 Nov 2017 Results summarizing the development (or identification) of post-baseline resistance (RAMs and antiretroviral phenotypic susceptibility) among subjects receiving darunavir QD dosing published in the HIV Clinical Trials
    • 16 Feb 2017 Results (n=2329) of seven phase 2 and 3 studies (ARTEMIS, GS-US-299-0102, ODIN, MONET,PROTEA, GS-US-216-0130,INROADS ) presented at the 24th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top